{"id":11454,"date":"2025-10-03T20:40:29","date_gmt":"2025-10-03T20:40:29","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-quality-of-life-qol\/"},"modified":"2025-10-04T08:15:34","modified_gmt":"2025-10-04T08:15:34","slug":"hypertermi-livskvalitet-qol","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/sv\/hypertermi-livskvalitet-qol\/","title":{"rendered":"Effekten av hypertermi p\u00e5 livskvalitet (QoL): Sm\u00e4rtlindring, minskad tr\u00f6tthet och adjuvanta immunologiska f\u00f6rdelar"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Effekten av hypertermi p\u00e5 livskvalitet (QoL): Sm\u00e4rtlindring, minskad tr\u00f6tthet och adjuvanta immunologiska f\u00f6rdelar\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"VD\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrum Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hypertermi, Onkologi, klinisk pr\u00f6vning Fas III, QoL, sm\u00e4rta, E-E-A-T\"\n      \/*... FAQPage Schema skulle l\u00e4ggas till separat f\u00f6r avsnittet Vanliga Fr\u00e5gor *\/\n    }\n<\/script><\/p>\n<article>\n<header>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Auktoritet och Expertis (EEAT): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Av <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sv\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, och <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sv\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Effekten av hypertermi p\u00e5 livskvalitet (QoL): Sm\u00e4rtlindring, minskad tr\u00f6tthet och adjuvanta immunologiska f\u00f6rdelar<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Inom modern onkologi str\u00e4var cancerbehandling efter den optimala balansen mellan<a href=\"https:\/\/andromedichyperthermia.com\/sv\/hypertermi-overlevnad-cancerpatienter\/\"> \u00d6verlevnad (OS\/DFS)<\/a> och <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Livskvalitet (QoL).<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Hypertermi (HT) representerar en unik adjuvant modalitet, som genom stora kliniska pr\u00f6vningar ( <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sv\/hypertermi-fas-iii-studier\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Randomiserade kontrollerade pr\u00f6vningar Fas III (RCT)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ) har visat sig f\u00f6rb\u00e4ttra QoL p\u00e5 flera niv\u00e5er: symptomkontroll, allm\u00e4n funktionell status och en utm\u00e4rkt s\u00e4kerhetsprofil.<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Stor Palliativ F\u00f6rdel: Sm\u00e4rtkontroll (Evidensgrad A1 fr\u00e5n kliniska Fas III-pr\u00f6vningar)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Metastaserad skelettsm\u00e4rta f\u00f6rs\u00e4mrar QoL. Lokoregional RF-Hypertermi, kombinerat med Str\u00e5lterapi (RT), ger \u00f6verl\u00e4gsen palliativ kontroll, enligt <\/span><\/span><a href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">studien Fas III publicerad av Chi MS et al<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. (2017)[1]:<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL-Indikator\/Sm\u00e4rtf\u00f6rb\u00e4ttring<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapi<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hypertermi (HT)<\/span><\/span><\/th>\n<th>QoL-P\u00e5verkan<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Andel Komplett Respons (CR) efter 3 M\u00e5nader<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (noll sm\u00e4rtpo\u00e4ng)<\/span><\/span><\/td>\n<td>7,1 %<\/td>\n<td>37,9 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">533 % \u00f6kning av chanserna till total sm\u00e4rtlindring.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Varaktighet av Sm\u00e4rtlindring<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Median: 55 dagar\/7,9 veckor<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Median: Inte uppn\u00e5dd vid 24 veckor<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Varaktigheten av lindringen tredubblas, vilket minskar beroendet av sm\u00e4rtstillande medel.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00c5r <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226?via%3Dihub\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2024 publicerade Sahinbas och kollegor en Fas III-studie<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> f\u00f6r sm\u00e4rta vid skelettmetastaser, fr\u00e4mst fr\u00e5n br\u00f6st- och prostatacancer, med WBHT wIRA hypertermi ut\u00f6ver RT.[2]<\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Baserat p\u00e5 denna studie uppvisade gruppen som endast behandlades med str\u00e5lterapi (RT) den mest intensiva sm\u00e4rtan. Studien avslutades efter att totalt 61 patienter inkluderats, 5 \u00e5r efter den f\u00f6rsta inkluderingen (april 2016 \u2013 februari 2021). Slutligen visade CR-frekvensen i gruppen RT + WBH den mest signifikanta skillnaden j\u00e4mf\u00f6rt med enbart RT, 47,4% respektive 5,3%, inom 2 m\u00e5nader efter behandlingen (P-v\u00e4rde &lt; 0,05). Tiden till komplett sm\u00e4rtlindring var 10 dagar f\u00f6r RT + WBH, medan slutpunkten inte uppn\u00e5ddes i gruppen RT monoterapi. Sm\u00e4rtprogression eller sjukdomsstabilitet observerades hos h\u00e4lften av patienterna i RT-gruppen inom 4 veckor efter behandlingen. Denna po\u00e4ng var dock n\u00e4ra noll hos RT + WBHT-patienter inom tv\u00e5 m\u00e5nader efter behandlingen.<\/span><\/span><\/span><\/p>\n<p><strong class=\"sub-title\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Slutsatser:\u00a0<\/span><\/span><\/span><\/strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> WBH plus RT visade signifikanta \u00f6kningar av sm\u00e4rtlindring och kortare responstid j\u00e4mf\u00f6rt med enbart RT hos patienter med metastaserade skelettskador.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL-Indikator\/Sm\u00e4rtf\u00f6rb\u00e4ttring<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapi<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hypertermi (WBHT wIRA)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL-P\u00e5verkan<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Andel Komplett Respons (CR) efter 2 m\u00e5nader<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (noll sm\u00e4rtpo\u00e4ng)<\/span><\/span><\/td>\n<td>5,3 %<\/td>\n<td>47,4 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">894 % \u00f6kning<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * av chanserna till total sm\u00e4rteliminering.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tid till komplett sm\u00e4rtlindring<\/span><\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">uppn\u00e5ddes ej<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">10 dagar<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\">Betydande och Snabb F\u00f6rdel<\/span><\/strong><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Varaktighet av Sm\u00e4rtlindring\u00a0<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Median: 28 dagar\/4 veckor hos h\u00e4lften av patienterna<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Median: Inte uppn\u00e5dd vid 24 veckor<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Varaktigheten av lindringen * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00f6kar sexfaldigt<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> *, vilket minskar beroendet av sm\u00e4rtstillande medel.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. F\u00f6rb\u00e4ttrad Funktionell Status och Minskad Tr\u00f6tthet<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">F\u00f6rdelen med HT p\u00e5 QoL \u00e4r direkt m\u00e4tbar genom standardiserade fr\u00e5geformul\u00e4r (EORTC QLQ-C30), vilket visar en f\u00f6rb\u00e4ttring av det allm\u00e4nna tillst\u00e5ndet (Fysisk Funktion, Tr\u00f6tthet och \u00c5ngest):<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Signifikant F\u00f6rb\u00e4ttrad QoL (modulerad RF hypertermi mHT):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> En randomiserad klinisk pr\u00f6vning av Modulerad RF-Hypertermi (mEHT) vid livmoderhalscancer (LACC) rapporterade en signifikant f\u00f6rb\u00e4ttring av l\u00e5ngsiktiga QoL-po\u00e4ng, d\u00e4r patienter rapporterade b\u00e4ttre po\u00e4ng p\u00e5 skalorna f\u00f6r Fysisk och Emotionell Funktion.[3]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tr\u00f6tthetskontroll och Immunmodulering:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Helkroppshypertermi (WBHT) och HT i allm\u00e4nhet p\u00e5verkar kronisk tr\u00f6tthet (CRF) positivt genom att modulera proinflammatoriska cytokiner (IL-6, TNF-alfa). HT hj\u00e4lper ocks\u00e5 till att uppr\u00e4tth\u00e5lla och f\u00f6rb\u00e4ttra po\u00e4ngen p\u00e5 skalorna f\u00f6r Fysisk och Emotionell Funktion p\u00e5 l\u00e5ng sikt.[4]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Snabb Emotionell \u00c5terh\u00e4mtning (HIPEC):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Efter st\u00f6rre kirurgiska ingrepp som inkluderar HT (HIPEC), tenderar den emotionella QoL att f\u00f6rb\u00e4ttras snabbt, redan *3 m\u00e5nader postoperativt, ofta \u00f6verstigande baslinjeniv\u00e5erna.[5]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Konsolidering av L\u00e5ngsiktiga QoL-F\u00f6rdelar<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Data fr\u00e5n verkliga kliniska fall och kliniska pr\u00f6vningar vid avancerad cancer st\u00e4rker hypertermins roll i att stabilisera och f\u00f6rb\u00e4ttra QoL p\u00e5 l\u00e5ng sikt:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kurativ P\u00e5verkan vid 12 M\u00e5nader:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> En omfattande analys av patienter behandlade med kurativ intention (RCT + HT) visade en signifikant f\u00f6rb\u00e4ttring, som uppr\u00e4tth\u00f6lls under en *12-m\u00e5nadersperiod, i po\u00e4ngen p\u00e5 QoL-delsskalor som bed\u00f6mer **Emotionell Funktion, Social Funktion* och *S\u00f6mnst\u00f6rning (SL)*, j\u00e4mf\u00f6rt med EORTC:s onkologiska referenspopulation .[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Palliativa F\u00f6rdelar:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> I ett palliativt sammanhang ledde till\u00e4gget av HT till standardbehandlingen till en kliniskt relevant f\u00f6rb\u00e4ttring av *Sm\u00e4rta (PA)* och en minskning av *Finansiella Sv\u00e5righeter (FI)* *3 m\u00e5nader efter behandlingen*, vilket bidrog till en b\u00e4ttre allm\u00e4n patientkondition .[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">F\u00f6rb\u00e4ttrad QoL vid Avancerad Sjukdom (Kolorektal Cancer):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> I en studie som utv\u00e4rderade H\u00f6gfrekvent Hypertermi assisterad av kemoterapi hos patienter med kolorektal cancer i mellan- och avancerat stadium, visade gruppen som fick kombinationen signifikant h\u00f6gre (f\u00f6rb\u00e4ttrade) QoL-po\u00e4ng efter 4 behandlingscykler, vilket visar att HT effektivt f\u00f6rb\u00e4ttrar QoL, ut\u00f6ver de terapeutiska effekterna, samtidigt som b\u00e4ttre s\u00e4kerhet bibeh\u00e5lls .[11]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Adjuvanta Biologiska F\u00f6rdelar och \u00d6verl\u00e4gset Terapeutiskt Index<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT maximerar behandlingens d\u00f6dlighet utan att signifikant \u00f6ka risken f\u00f6r allvarlig toxicitet (Grad 3-4), och bibeh\u00e5ller d\u00e4rmed ett h\u00f6gt Terapeutiskt Index:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Validerad S\u00e4kerhet (Fas III kliniska pr\u00f6vningar):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Meta-analyser inom livmoderhalscancer visar ingen signifikant skillnad i akut eller sen toxicitet (RR Toxicitet 1.01) [6]. S\u00e4kerhetsprofilen uppr\u00e4tth\u00e5lls vid rektalcancer[7] och i pr\u00f6vningar f\u00f6r pankreascancer[8] .<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Organbevarande:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Vid rektalcancer \u00f6kar till\u00e4gget av HT till neoadjuvant kemoradioterapi 5-\u00e5rs Kolostomifri \u00d6verlevnad (CFS) fr\u00e5n 69,0% till 87,7%, en stor funktionell QoL-f\u00f6rdel .[7]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Abskopal Effekt (Vaccinliknande):<\/strong> HT utl\u00f6ser immunogen celld\u00f6d, vilket frig\u00f6r V\u00e4rmechockproteiner (HSPs) som aktiverar cytotoxiska CD8+ T-celler. Denna systemiska immunologiska f\u00f6rst\u00e4rkning bidrar till kontroll av kvarvarande sjukdom och \u00e4r en v\u00e4sentlig adjuvansf\u00f6rdel .[9]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Slutsats: Patientcentrerad Terapi<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Integrering av Hypertermi i det onkologiska protokollet representerar en avancerad, evidensbaserad strategi som inte bara f\u00f6rb\u00e4ttrar \u00d6verlevnaden, utan ocks\u00e5 ger robust symptomkontroll och uppr\u00e4tth\u00e5ller Livskvaliteten. Sm\u00e4rtlindring, kontroll av tr\u00f6tthet och ett utm\u00e4rkt s\u00e4kerhetsprofil g\u00f6r HT till en v\u00e4sentlig del av den holistiska v\u00e5rden av den onkologiska patienten.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vi inbjuder dig att konsultera v\u00e5ra experter f\u00f6r att integrera Hypertermi i ditt protokoll, i syfte att maximera b\u00e5de effektiviteten och Livskvaliteten.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EEAT-F\u00f6rs\u00e4kran:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Detta inneh\u00e5ll baseras p\u00e5 publicerade data fr\u00e5n randomiserade och prospektiva kliniska Fas III-pr\u00f6vningar, med anv\u00e4ndning av standardiserade instrument f\u00f6r m\u00e4tning av Livskvalitet (EORTC QLQ-C30). Fullst\u00e4ndiga referenser \u00e4r integrerade med direkta l\u00e4nkar till k\u00e4llpublikationerna.<\/span><\/span><\/small><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Referenser:<\/span><\/span><\/p>\n<ol>\n<li>Chi MS, Yang KL, Chang YC, Ko HL, Lin YH, Huang SC, Huang YY, Liao KW, Kondo M, Chi KH. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87. doi: 10.1016\/j.ijrobp.2017.09.030. Epub 2017 Sep 21. PMID: 29066122.<\/li>\n<li>Faghihi Moghaddam F, Bakhshandeh M, Mofid B, Sahinbas H, Faeghi F, Mirzaei H, Rakhsha A, Yousefi Kashi AS, Sadeghi R, Mahdavi A. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. J Therm Biol. 2024 Feb;120:103804. doi: 10.1016\/j.jtherbio.2024.103804. Epub 2024 Feb 23. PMID: 38460451.<\/li>\n<li>Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers (Basel). 2022 Jan 27;14(3):656. doi: 10.3390\/cancers14030656. PMID: 35158924; PMCID: PMC8833695.<\/li>\n<li>Ostberg, K., et al. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol. 2008 Jul;27(7):849-56. doi: 10.1007\/s10067-007-0785-5. Epub 2007 Oct 20. PMID: 17948286.<\/li>\n<li>Morgan RB, Tun S, Eng OS. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a narrative review. Curr Probl Surg. 2020 Jan;57(1):100693. doi: 10.1016\/j.cpsurg.2019.100693. Epub 2020 Jan 29. PMID: 32063294.<\/li>\n<li>Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5;15(2):346. doi: 10.3390\/cancers15020346. PMID: 36672300; PMCID: PMC9856725.<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). <a href=\"https:\/\/doi.org\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/a><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li>Baronzio, G. F., et al. Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Front Oncol. 2020 Nov 24;10:591932. doi: 10.3389\/fonc.2020.591932. PMID: 33324545; PMCID: PMC7721869.<\/li>\n<li>Linnenbank, W. I., et al. Real-World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radiochemotherapy. Cancers (Basel). 2023 Feb 1;15(3):880. doi: 10.3390\/cancers15030880. PMID: 36765790; PMCID: PMC9954584.<\/li>\n<li>Liu, Z. Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncol Lett. 2019 Jan;17(1):215-220. doi: 10.3892\/ol.2018.9574. Epub 2018 Oct 12. PMID: 30655758; PMCID: PMC6313175.<\/li>\n<\/ol>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Auktoritet och Expertis (EEAT): Av Dr. Veronica Iatan , MD, och Cristian Gologan M.Sc , Andromedichyperthermia Effekten av hypertermi p\u00e5 livskvalitet (QoL): Sm\u00e4rtlindring, minskad tr\u00f6tthet och adjuvanta immunologiska f\u00f6rdelar Inom modern onkologi str\u00e4var cancerbehandling efter den optimala balansen mellan \u00d6verlevnad (OS\/DFS) och Livskvalitet (QoL). Hypertermi (HT) representerar en unik adjuvant modalitet, som genom stora kliniska&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[190,28,1023],"tags":[1024,1025,1026,351,1048,714,1029,1049,1030],"class_list":["post-11454","post","type-post","status-publish","format-standard","hentry","category-news-sv","category-okategoriserad","category-studii-clinice-sv","tag-calitatea-vietii-sv","tag-durere-sv","tag-hipertermie-oncologica-sv","tag-hypertermi-sv","tag-klinisk-provning-fas-iii","tag-onkologi","tag-qol-sv","tag-smarta","tag-studii-faza-iii-sv"],"gutentor_comment":1,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/sv\/wp-json\/wp\/v2\/posts\/11454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sv\/wp-json\/wp\/v2\/comments?post=11454"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/sv\/wp-json\/wp\/v2\/posts\/11454\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/sv\/wp-json\/wp\/v2\/media?parent=11454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sv\/wp-json\/wp\/v2\/categories?post=11454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sv\/wp-json\/wp\/v2\/tags?post=11454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}